Haisco Pharmaceutical Group Co., Ltd.

SZSE:002653 Stock Report

Market Cap: CN¥49.2b

Haisco Pharmaceutical Group (002653) Stock Overview

Researches, develops, manufactures, and sells pharmaceutical products in China. More details

002653 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends2/6

002653 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Haisco Pharmaceutical Group Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Haisco Pharmaceutical Group
Historical stock prices
Current Share PriceCN¥44.35
52 Week HighCN¥48.89
52 Week LowCN¥25.48
Beta-0.12
1 Month Change-4.52%
3 Month Change-2.36%
1 Year Change42.33%
3 Year Change171.59%
5 Year Change82.89%
Change since IPO529.57%

Recent News & Updates

Recent updates

An Intrinsic Calculation For Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) Suggests It's 30% Undervalued

Mar 24
An Intrinsic Calculation For Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) Suggests It's 30% Undervalued

Is Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) Trading At A 38% Discount?

Dec 19
Is Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) Trading At A 38% Discount?

Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) Shares May Have Run Too Fast Too Soon

Nov 19
Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) Shares May Have Run Too Fast Too Soon

Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

Aug 22
Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

With Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) It Looks Like You'll Get What You Pay For

Jul 25
With Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) It Looks Like You'll Get What You Pay For

Shareholder Returns

002653CN PharmaceuticalsCN Market
7D-0.9%1.1%1.7%
1Y42.3%25.1%24.6%

Return vs Industry: 002653 exceeded the CN Pharmaceuticals industry which returned 25.1% over the past year.

Return vs Market: 002653 exceeded the CN Market which returned 24.6% over the past year.

Price Volatility

Is 002653's price volatile compared to industry and market?
002653 volatility
002653 Average Weekly Movement7.2%
Pharmaceuticals Industry Average Movement4.9%
Market Average Movement5.0%
10% most volatile stocks in CN Market8.6%
10% least volatile stocks in CN Market2.8%

Stable Share Price: 002653's share price has been volatile over the past 3 months compared to the CN market.

Volatility Over Time: 002653's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of CN stocks.

About the Company

FoundedEmployeesCEOWebsite
20055,337Xiu Lian Fanwww.haisco.com

Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products in China. The company offers anesthetic analgesic, neuropsychiatric system, and digestive liver and parenteral nutrition medications; drugs for the endocrine and cardiovascular system; oncology-related drugs; andrology drugs; desonide and liprocaine cream; propofol medium/long chain fat emulsion and hydroxyethyl starch sodium chloride injection; sodium fusidicate ointment; lupatadine fumarate tablets; and caspofungin acetate and methylprednisolone sodium succinate for injection. It also develops Sisuning for sedation and anesthesia during surgery/procedure for non-endotracheal intubation, general anesthesia induction and maintenance, sedation in mechanical ventilation during intensive care, pediatric indications, and general anesthesia induction; Simenine for diabetic peripheral neuralgia, postherpetic neuralgia, and central nervous system analgesia; Beichangping for type 2 diabetes; Sysojing for postoperative analgesia of abdominal surgery, chronic kidney disease itching, orthopedic analgesia, and postoperative nausea and vomiting; HSK31858 for non-cystic fibrosis bronchiectasis, bronchial asthma, chronic obstructive pulmonary disease, and expectorant; HSK31679 for nonalcoholic steatohepatitis; HSK39297 for PHN of hemolytic disease and primary or secondary glomerular disease; HSK39775 and HSK42360 for advanced solid tumors; HSK39004 and HL231 for chronic obstructive pulmonary disease; HSK44459 for interstitial lung disease; HSK46575 for prostate cancer; and HSK41959 for advanced solid tumors.

Haisco Pharmaceutical Group Co., Ltd. Fundamentals Summary

How do Haisco Pharmaceutical Group's earnings and revenue compare to its market cap?
002653 fundamental statistics
Market capCN¥49.20b
Earnings (TTM)CN¥350.11m
Revenue (TTM)CN¥3.86b
140.5x
P/E Ratio
12.7x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
002653 income statement (TTM)
RevenueCN¥3.86b
Cost of RevenueCN¥1.09b
Gross ProfitCN¥2.77b
Other ExpensesCN¥2.42b
EarningsCN¥350.11m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Aug 23, 2025

Earnings per share (EPS)0.32
Gross Margin71.72%
Net Profit Margin9.07%
Debt/Equity Ratio53.6%

How did 002653 perform over the long term?

See historical performance and comparison

Dividends

0.9%
Current Dividend Yield
134%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/13 13:17
End of Day Share Price 2025/07/11 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Haisco Pharmaceutical Group Co., Ltd. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shanshan LiChina Merchants Securities Co. Ltd.
Chao LiCitic Securities Co., Ltd.
Qianli MaGuosen Securities Co., Ltd.